1150618-42-0

Basic information

• Product Name: tert-Butyl 2-methylpiperidin-3-ylcarbamate
• Synonyms: tert-Butyl 2-methylpiperidin-3-ylcarbamate;(2-Methyl-piperidin-3-yl)-carbaMic acid tert-butyl ester
• CAS NO: 1150618-42-0
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.30458
• Mol File: 1150618-42-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 308.407 °C at 760 mmHg
• Flash Point: 140.32 °C
• Appearance: /
• Density: 1.00
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: tert-Butyl 2-methylpiperidin-3-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 2-methylpiperidin-3-ylcarbamate(1150618-42-0)
• EPA Substance Registry System: tert-Butyl 2-methylpiperidin-3-ylcarbamate(1150618-42-0)

Safety Data

• Hazardous Substances Data: 1150618-42-0(Hazardous Substances Data)

Usage

General Description

Tert-butyl 2-methylpiperidin-3-ylcarbamate is a chemical compound with the molecular formula C12H24N2O2. It is commonly used as a pharmaceutical intermediate in the synthesis of various drugs and medications. tert-butyl 2-methylpiperidin-3-ylcarbamate is a derivative of piperidine, which is a heterocyclic amine compound. Tert-butyl 2-methylpiperidin-3-ylcarbamate has been studied for its potential therapeutic properties, including its role in the treatment of neurological disorders and as a potential antiviral agent. However, further research is needed to fully understand its pharmacological effects and potential applications in medical treatment.

Upstream product

• 912368-78-6 tert-butyl ((1S)-1-acetyl-4-{[(benzyloxy)carbonyl]amino}butyl)carbamate 
• 2480-93-5 Boc-Orn(Z)-OH 
• 1219095-87-0 tert-butyl N-(2-methylpyridin-3-yl)carbamate 

Relevant articles and documents

Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors

Checkpoint kinase 1 (CHK1) inhibitors are potential cancer therapeutics that can be utilized for enhancing the efficacy of DNA damaging agents. Multiple small molecule CHK1 inhibitors from different chemical scaffolds have been developed and evaluated in clinical trials in combination with chemotherapeutics and radiation treatment. Scaffold morphing of thiophene carboxamide ureas (TCUs), such as AZD7762 (1) and a related series of triazoloquinolines (TZQs), led to the identification of fused-ring bicyclic CHK1 inhibitors, 7-carboxamide thienopyridines (7-CTPs), and 7-carboxamide indoles. X-ray crystal structures reveal a key intramolecular noncovalent sulfur-oxygen interaction in aligning the hinge-binding carboxamide group to the thienopyridine core in a coplanar fashion. An intramolecular hydrogen bond to an indole NH was also effective in locking the carboxamide in the preferred bound conformation to CHK1. Optimization on the 7-CTP series resulted in the identification of lead compound 44, which displayed respectable drug-like properties and good in vitro and in vivo potency.

HETEROCYCLIC TYROSINE KINASE INHIBITORS

The present invention provides compounds useful as inhibitors of Tec family kinases, compositions thereof, and methods of using the same. In certain embodiments, the present invention provides pharmaceutical formulations comprising provided compounds. In certain embodiments, the present invention provides a method of decreasing enzymatic activity of a Tec kinase family member. In some embodiments, such methods include contacting a Tec kinase family member with an effective amount of a Tec kinase family member inhibitor. In certain embodiments, the present invention provides a method of treating a disorder responsive to Tec kinase family inhibition in a subject in need thereof.